Novo Nordisk A/S (NYSE:NVO) Shares Gap Down – Should You Sell?

Novo Nordisk A/S (NYSE:NVOGet Free Report)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $84.62, but opened at $82.92. Novo Nordisk A/S shares last traded at $82.12, with a volume of 1,395,488 shares traded.

Analyst Ratings Changes

NVO has been the topic of a number of research reports. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a report on Monday, January 6th. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $140.20.

View Our Latest Stock Analysis on Novo Nordisk A/S

Novo Nordisk A/S Trading Down 4.5 %

The business has a 50 day simple moving average of $99.84 and a two-hundred day simple moving average of $118.61. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The stock has a market cap of $362.46 billion, a price-to-earnings ratio of 26.14, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45.

Institutional Investors Weigh In On Novo Nordisk A/S

Hedge funds have recently bought and sold shares of the business. Strategic Investment Solutions Inc. IL acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter worth approximately $25,000. Daiwa Securities Group Inc. acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $28,000. Abound Wealth Management grew its position in shares of Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after acquiring an additional 157 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $42,000. Finally, Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter worth approximately $48,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Company Profile

(Get Free Report)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Featured Stories

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.